Lower the Flow to see even more
DMPK workflows, not workarounds
Current LC-MS/MS platforms can routinely achieve sub ng/mL levels of sensitivity for large molecule bioanalysis. However, as therapeutic modalities become more effective, or as the delivery mechanism changes from IV to oral, there is an increasing demand for bioanalytical workflows that can achieve even lower levels of sensitivity.
Join us to learn how moving to microflow can allow you to improve your limits of quantification, and unlock the full potential of the complete, end-to-end bioanalytical workflow.
Topics we’ll explore
- Advantages of using microflow to improve sensitivity for large molecule bioanalysis
- Key learnings for deploying microflow LC-MS/MS in routine bioanalytical environments
- How using microflow can help reduce solvent usage, increase cost savings and reduce environmental footprint
Who should attend
This webinar is designed for Research Associates, Scientists, Directors, Lab managers in pharma, biopharma, biotech and contract research organizations performing bioanalysis.
Speaker: Dr. Robert Plumb (Scientific Advisor, DMPK, Pharma Quan Program, Waters Corporation)
Dr Plumb is currently a scientific advisor in the LCMS Business Unit at Waters Corporation. He has several years of experience in the pharmaceutical industry beginning in 1987 at Glaxo R&D DMPK Department focusing on regulatory bioanalysis and metabolite identification.
In 2001 he moved to Waters Corporation in Milford, MA, USA where he has worked in R&D, pharmaceutical business development, metabolic phenotyping and discovery omics.
Research interest includes application of fast chromatography and advanced mass spectrometry in bioanalysis and omics studies. Dr Plumb has published over 150 papers on LC/MS(MS) and NMR for bioanalysis, metabolomics and metabolite identification.
Speaker: Nikunj Tanna (Pharma Marketing Manager, Waters Corporation)
Nikunj Tanna is the Pharma Marketing Manager at Waters corporation. His role at Waters focuses on complete workflow solutions for quantitation of small and large molecules.
These end-to-end workflows include automation, novel sample preparation and chromatographic separation approaches, followed by detection using TQ platforms.
